Certmedica International hat die COFEPRIS-Zulassung für die formoline L112-Serie in Mexiko erhalten. Die Produkte (500 mg und 750 mg) sind Medizinprodukte der Klasse III zur Behandlung von Übergewicht und Adipositas. Angesichts hoher Adipositasraten bieten sie eine sichere Option zur Gewichtsreduktion und werden bis Mitte 2025 in über 6.000 Apotheken und Kliniken eingeführt.
Certmedica International has received COFEPRIS approval for its formoline L112 product series in Mexico, which includes two doses, 500 mg and 750 mg, classified as Class III medical devices for treating overweight and obesity. With Mexico's high obesity rates, the products offer a safe, effective weight-loss option, set for launch in over 6,000 pharmacies and clinics by mid-2025.
At ArabHealth, our COO Dr. Marcus Furch had the opportunity to discuss several of Certmedica's key initiatives, including our internationalization strategy, clinical studies, and product development focus on metabolic syndrome. He also highlighted our use of digital platforms and announced launch of the digital medical product, the My-formoline app, in Germany.
The accompanying interview is av
